ReviewAntioxidants (Basel, Switzerland)2020
Could Ergothioneine Aid in the Treatment of Coronavirus Patients?
Review in Antioxidants (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Higher Mushroom Consumption Is Associated with Lower Risk of Cancer: A Systematic Review and Meta-Analysis of Observational Studies.Advances in nutrition (Bethesda, Md.) · 2021Pooled it
- Plasma as Proxy for Tissue Metabolism When Extending Lifespan in Mice.Metabolites · 2026Article
- Advances and prospects of ergothioneine in the treatment of cognitive frailty.Annals of medicine · 2025Review
- A Review of Novel Antioxidant Ergothioneine: Biosynthesis Pathways, Production, Function and Food Applications.Foods (Basel, Switzerland) · 2025Review
- The Current Situation and Future Trends of Ergothioneine in Biology and Medical Research: A Bibliometric Analysis.Journal of multidisciplinary healthcare · 2025Review
- The Role of Ergothioneine in Red Blood Cell Biology: A Review and Perspective.Antioxidants (Basel, Switzerland) · 2024Review
- Impact of aging and ergothioneine pre-treatment on naphthalene toxicity in lung.Toxicology letters · 2024Article
- Ergothioneine and its congeners: anti-ageing mechanisms and pharmacophore biosynthesis.Protein & cell · 2024Review
- Understanding mechanisms of antioxidant action in health and disease.Nature reviews. Molecular cell biology · 2024Review
- Biochemical and Structural Characterization of OvoAACS catalysis · 2023Article
- An S=1 Iron(IV) Intermediate Revealed in a Non-Heme Iron Enzyme-Catalyzed Oxidative C-S Bond Formation.Angewandte Chemie (International ed. in English) · 2023Article
- Safe and Effective Antioxidant: The Biological Mechanism and Potential Pathways of Ergothioneine in the Skin.Molecules (Basel, Switzerland) · 2023Review
- Article
- The potential role of ischaemia-reperfusion injury in chronic, relapsing diseases such as rheumatoid arthritis, Long COVID, and ME/CFS: evidence, mechanisms, and therapeutic implications.The Biochemical journal · 2022Review
- Low Plasma Ergothioneine Predicts Cognitive and Functional Decline in an Elderly Cohort Attending Memory Clinics.Antioxidants (Basel, Switzerland) · 2022Article
- Ergothioneine: A Stress Vitamin with Antiaging, Vascular, and Neuroprotective Roles?Antioxidants & redox signaling · 2022Review
- Reactive Sulfur Compounds in the Fight against COVID-19.Antioxidants (Basel, Switzerland) · 2022Review
- Toward more efficient ergothioneine production using the fungal ergothioneine biosynthetic pathway.Microbial cell factories · 2022Article
- AggMapNet: enhanced and explainable low-sample omics deep learning with feature-aggregated multi-channel networks.Nucleic acids research · 2022Article
- Health-Promoting Properties of Medicinal Mushrooms and Their Bioactive Compounds for the COVID-19 Era-An Appraisal: Do the Pro-Health Claims Measure Up?Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Infection with SARS-CoV-2 causes the coronavirus infectious disease 2019 (COVID-19), a pandemic that has, at present, infected more than 11 million people globally. Some COVID-19 patients develop a severe and critical illness, spurred on by excessive inflammation that can lead to respiratory or multiorgan failure. Numerous studies have established the unique array of cytoprotective properties of the dietary amino acid ergothioneine. Based on studies in a range of in vitro and in vivo models, ergothioneine has exhibited the ability to modulate inflammation, scavenge free radicals, protect against acute respiratory distress syndrome, prevent endothelial dysfunction, protect against ischemia and reperfusion injury, protect against neuronal damage, counteract iron dysregulation, hinder lung and liver fibrosis, and mitigate damage to the lungs, kidneys, liver, gastrointestinal tract, and testis, amongst many others. When compiled, this evidence suggests that ergothioneine has a potential application in the treatment of the underlying pathology of COVID-19. We propose that ergothioneine could be used as a therapeutic to reduce the severity and mortality of COVID-19, especially in the elderly and those with underlying health conditions. This review presents evidence to support that proposal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.